Routine interferon-neutralising antibody testing inpatients with relapsing-remitting multiple sclerosis

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 2, 2010, Pages 105-110

  Foley, P ^a   Reilly, P ^a   Coulson, A ^a   O'Riordan, J I ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Interferon; Multiple sclerosis; Neutralising antibody

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT ASSESSMENT; TREATMENT DURATION;

ADULT; ANTIBODIES, NEUTRALIZING; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SCOTLAND; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 77955601629     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.203     Document Type: Article

References (18)

1. Compston A, Confavreux C, Lassmann H, editors. McAlpine's multiple sclerosis. 4th ed. Edinburgh: Churchill Livingstone; 2006.
2. Farrell R, Giovannoni G. Measuring and management of antiinterferon beta antibodies in subjects with multiple sclerosis. Mult Scler 2007; 12:567-77.doi:10.1177/1352458506073522
3. Teitelbaum D, Brenner T, Abramsky O et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003; 9:592-9. doi:10.1191/1352458503ms963oa
4. Sominanda A, Hillert J, Fogdell-Hahn A. Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent. Eur J Neurol 2009; 16:21-6. doi:10.1111/j.1468-1331.2008.02264.x
5. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001; 56:1628-36. Erratum in: Neurology 2001; 57:1146.
6. The IFNB Multiple Sclerosis Study Group. Interferon beta-1B is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-61.
7. Sorensen P, Ross C, Clemmensen KM et al Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362:1184-91. doi:10.1016/S0140-6736(03)14541-2
8. Sørensen PS, Deisenhammer F, Duda P et al. Guidelines on the use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12:817-27. doi:10.1111/j.1468-1331.2005.01386.x
9. Association of British Neurologists (ABN). ABN Guidelines for treatment of multiple sclerosis with β-interferon and glatiramer acetate. London: ABN; 2007.
10. Mikol DD, Barkhof F, Chang P et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903-14. doi:10.1016/S1474-4422(08)70200-X
11. SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS) study group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56:1496-504.
12. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-7.
13. The North American Study Group on interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63:1788-95.
14. Clanet M, Kappos L, Hartung HP et al. Interferon beta 1-a in relapsing multiple sclerosis: four-year extension of the European IFN beta-1a dose-comparison study. Mult Scler 2004; 10:139-44. doi:10.1191/1352458504ms990oa
15. Kappos L, Clanet M, Sandberg-Wollheim M et al. Neutralizing antibodies and the efficacy of interferon beta-1a - a 4-year controlled study. Neurology 2005; 65:40-7. doi:10.1212/01. wnl.0000171747.59767.5c
16. Burks JS, Noronha A. Guidelines on the use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task force on IFN-B antibodies in multiple sclerosis. Eur J Neurol 2007; 14:e8-9. doi:10.1111/j.1468-1331.2007.01782.x
17. Durelli L, Barbero P, Bergui M. MRI activity and neutralising antibodies as predictors of response to interferon beta treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:646-51. doi:10.1136/jnnp.2007.130229
18. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009; 23:379-96. doi:10.2165/00023210-200923050-00003